Table 3 Study of iguratimod in lupus nephritis discontinue criteria

1

Participants experiencing serious adverse reactions during the study

2

Fatal comorbidities happen, including but not limited to severe infection

3

Participants whose condition deteriorates within the first 24 week

4

Participants who fail to achieve remission (CR or PR) until the end of week 24

5

Pregnant

6

Any other circumstances under which the investigator considers the patient to be unable to finish the study